How frequently should vitamin B12 and folate be measured in adults, taking into account risk factors such as strict vegan diet, gastrointestinal disease, medication use, pregnancy, and advanced age?

How Often to Check B12 and Folate

In adults without risk factors, routine screening for vitamin B12 and folate is not recommended; however, high-risk populations require targeted initial screening and ongoing monitoring based on their specific condition. 1, 2, 3

Initial Screening: Who Needs Testing

High-Risk Populations Requiring Screening

• Adults >75 years should be screened due to 18–25% prevalence of metabolic B12 deficiency in this age group 1
• Metformin use >4 months warrants screening, as it increases B12 deficiency risk approximately 3-fold 1, 2
• PPI or H2-blocker use >12 months requires screening due to impaired B12 absorption 1, 2
• Strict vegans or vegetarians need screening for dietary B12 insufficiency 1, 2
• Post-bariatric surgery patients require screening due to permanent malabsorption 1, 4
• Ileal resection >20 cm or Crohn's disease with ileal involvement mandates screening 1, 4
• Autoimmune hypothyroidism requires screening at diagnosis, with 28–68% prevalence of B12 deficiency 1

Clinical Presentations Requiring Testing

• Macrocytic anemia (MCV >100 fL) on complete blood count 1, 5
• Neurological symptoms: paresthesias, numbness, gait disturbance, cognitive difficulties, memory problems 1, 2
• Glossitis or oral symptoms (tongue pain, fissuring) 1
• Unexplained fatigue in high-risk patients 1

Ongoing Monitoring Frequency

Post-Bariatric Surgery Patients

• Every 3 months during the first year (at 3,6, and 12 months), then annually thereafter 1, 4
• Every 3 months during pregnancy if planning conception or pregnant 4
• Check concurrent micronutrients (iron, folate, vitamin D, thiamine) at same intervals 1

Autoimmune Thyroid Disease

• Annual B12 screening for all patients with autoimmune hypothyroidism due to progressive autoimmune gastritis 1
• Recheck 3–6 months after initial treatment to confirm normalization 1

Crohn's Disease with Ileal Involvement

• Annual screening for patients with ileal Crohn's disease, especially if >30–60 cm of ileum is involved 1, 4

Patients on Long-Term Medications

• Annual monitoring for patients on metformin >4 months or PPIs/H2-blockers >12 months 1

Patients Receiving B12 Replacement Therapy

• First recheck at 3 months after initiating supplementation 4
• Second recheck at 6 months to detect treatment failures early 4
• Third recheck at 12 months to ensure stabilization 4
• Annual monitoring thereafter once levels stabilize 1, 4
• Measure serum B12, complete blood count, and homocysteine (target <10 μmol/L) at each visit 1, 4

Patients with Permanent Malabsorption

For patients with pernicious anemia, total gastrectomy, ileal resection >20 cm, or post-bariatric surgery, lifelong supplementation is required with the following monitoring schedule:

• Every 3 months in the first year (at 3,6, and 12 months) 1, 4
• Annually thereafter for life 1, 4
• Check folate, iron studies, and vitamin D concurrently 1

Folate Monitoring Considerations

When to Check Folate

• Always check folate concurrently with B12 in patients with macrocytic anemia 1, 5
• Never give folic acid before confirming adequate B12 status, as folate can mask B12 deficiency anemia while allowing irreversible neurological damage 1, 4

Folate-Specific Risk Factors

• Inflammatory bowel disease requires annual folate screening 1
• Chronic alcoholism warrants folate assessment 6
• Medications (methotrexate, sulfasalazine, anticonvulsants) require monitoring 1

Critical Monitoring Pitfalls

• Do not stop monitoring after one normal result in patients with malabsorption, as they often relapse 4
• Do not rely solely on serum B12 in elderly patients (>60 years), as up to 50% with "normal" serum B12 have metabolic deficiency on MMA testing 1
• Measure methylmalonic acid (MMA) when B12 is borderline (180–350 pg/mL) to confirm functional deficiency 1
• Check homocysteine to assess functional B12/folate status, targeting <10 μmol/L 1, 4

Average-Risk Adults

Routine screening of asymptomatic, average-risk adults is not recommended by any major medical organization, including the U.S. Preventive Services Task Force. 2, 3 Testing should be reserved for symptomatic patients or those with specific risk factors outlined above.